Management

Read about our leadership team, Ribocure board and Science board below. 

Leadership team

Dr. Li-ming Gan

Chief Executive Officer

MD, PhD

Chief Executive Officer , Ribocure Pharmaceuticals AB President of Global R&D and Chief Medical Officer, Suzhou Ribo Life Science Co., Ltd.
 
Li-ming Gan is a physician scientist and has 20 years of pharma experience from AstraZeneca. He was responsible for the atherosclerosis and heart failure pipeline between 2007-2011. Between 2011-2013, he worked as a Translational Science Director to help bridging the early projects into the human setting. Between 2013-2018, Li-ming was appointed as a Senior Director Physician, and later Chief Scientist in early clinical research unit and was responsible for phase I and II clinical programs within the cardiovascular area. Until 31st of Dec 2021, Li-ming was VP and Head of Early Clinical Development in early Cardiovascular, Renal and Metabolism Biopharmaceuticals R&D AstraZeneca. Academically Li-ming holds a part-time position as professor and Chief physician at the department of cardiology, Sahlgrenska University Hospital and Sahlgrenska Academy, University of Gothenburg.
 
Since 1st of January 2022, Li-ming joined Suzhou Ribo Life Science Co., Ltd. as President of Global R&D and Chief Medical Officer to devote his career and research focusing on RNA therapeutics. With his joining of Suzhou Ribo Life Science Co., Ltd. Li-ming has also been appointed as CEO for Ribocure Pharmaceuticals AB, a newly established international R&D center of Suzhou Ribo Life Science Co., Ltd. based in Gothenburg, Sweden. This unit will be devoting to developing Suzhou Ribo Life Science Co., Ltd.´s innovative drug projects on the global arena through close collaboration with Scandinavian and European academia and biotechs, global project leadership, as well as innovative clinical development approaches.

Dr. Anders Gabrielsen

Chief Medical Officer and Head of Global Clinical Development & Medical Affairs

MD, PhD

Anders Gabrielsen, MD, DMSc, Associate Professor, is a physician scientist with 10+ years of industry experience across the CVRM therapy area. Cardiologist and Internist by training at Karolinska Institutet and Karolinska University Hospitals, with subspecialty in heart failure and core clinical team duties across all aspects of cardiology and internal medicine. Long-standing research experience with translational cardiovascular research focusing on heart failure, pathophysiology, translational vascular biology, atherosclerosis and inflammation with explorative studies including target ID and biomarker exploration studies. Extensive global pharma industry experience working with Bayer, Novartis and AstraZeneca covering multiple CVRM development MoA’s, indications and launches. In the latest role with AstraZeneca served as executive group director for early clinical development with responsibility for cardiovascular and heart failure project clinical activities.

Dr. Sara Svedlund

Head of Ribocure Clinic & Senior Medical Director

MD, PhD

Head of Ribocure Clinic, Ribocure Pharmaceuticals AB.

Sara Svedlund is chief physician and associate professor in non-invasive cardiology, Sahlgrenska University Hospital and Sahlgrenska Academy, University of Gothenburg. Sara has 15 years of clinical experience as physician and is specialized in cardiovascular, exercise and pulmonary physiology. She was licensed physician in 2011 and defended her thesis the same year. Sara became a medical specialist in 2017 and was appointed associate professor in 2019. She was Care Unit Chief Physician at the Clinical Department for Cardiopulmonary Physiology at Sahlgrenska University Hospital during 2016-2022. Research wise, Sara has focused on clinical trials, development and validation of different methodological aspects as well as identification of mechanisms and biomarkers in different cardiovascular patient populations. Further, she has worked extensively with methodological alignment in clinical trials and run an academic echocardiography core lab between 2015-2022. Since March 2022 she is Head of Clinical Operations at Ribocure.

Rebeckha Magnusson

Head of Clinical Operations & Quality Assurance

Head of Clinical Operations & Quality Assurance, Ribocure Pharmaceuticals AB.
 
Rebeckha Magnusson has worked in the Clinical Development area for more than 15 years. She has an extensive and broad experience from various positions, mainly within Clinical Operations and Project Management, in both big Pharmaceutical and small Biotech companies such as AstraZeneca and IRLAB. Most recent position as Clinical Project Director at Sobrera Pharma and Head of Clinical Operations at Antaros Medical. Rebeckha is certified in Lean Six sigma and has led several successful process improvement projects within the R&D area. Rebeckha has a broad experience also within the Regulatory and QA field as responsible for compound regulatory strategies, leading a successful IND submission as well as setting up and maintain the Quality Management System at several small Biotech companies.

Maria Liljevald

Head of Global Regulatory Affairs

BSc

Maria Liljevald holds a BSc in molecular biology at the University of Gothenburg and she has 20 years of experience in the pharmaceutical industry. She started her career at AstraZeneca as a lab-based molecular biologist in the transgenic research laboratory in 2004. She moved into preclinical Toxicology 2012. As a Global Toxicology Project Lead, Maria supported drug projects from pre-clinical up to Ph2b, covering various modalities such as oligos, small molecules and Fixed Dose Combination programs in a variety of therapeutic areas. Based on her expertise and experience, she has been on the European Register of Toxicologist (ERT) since 2019. In 2021 Maria took the role as Global Regulatory Lead supporting projects from pre-clinical into Ph2b. She has successfully steered projects through multiple INDs, global Ph2 clinical trial applications, and Health Authority interactions. Recently Maria took on a role as European Regulatory Affairs Lead for a project in the late stage of Ph3 preparing for MAA application. Maria joined Ribocure Pharmaceutical AB in June 2023 as Head of Global Regulatory Affairs.

Dr. Lotta Egnell

Global Head of DMPK & Clinical Pharmacology

MSc, PhD

Lotta (Ann-Charlotte) Egnell has extensive senior leadership experience in Clinical Pharmacology and DMPK with 20 years big pharma industry experience in the CVRM therapy area. Lotta is a pharmacist by training at Uppsala University, Sweden and holds a PhD in translational and computational modeling of atypical enzyme kinetics of drug metabolizing cytochrome P450s from the University of Manchester, UK. Lotta has led the implementation of model based preclinical drug discovery approaches within the CVRM research area at AstraZeneca, and more recently led a team of Clinical Pharmacology Scientists and Clinical Pharmacometricians, supporting a model based clinical development, impacting decision making from Ph1 up to life cycle management. Her project impact spans several different modalities, and from target selection to life cycle management. Lotta also holds a Master in Leadership and Organization, and has extensive line management as well as project leadership experience.

Dr. Johannes Wikström

Head of Bioscience and Global projects

MSc, PhD

Johannes Wikström is a biologist with 15 years of pharma experience from AstraZeneca. He has led bioscience work in early cardiovascular drug projects from target identification and validation and up to regulatory filing and progress of drug projects to clinical Ph2, where he has recent experience of leading a Ph2b Chronic kidney disease project as Global project leader. Johannes was appointed cardiovascular in vivo Team leader in 2011, and from 2019 he held a Principal scientist role. He has been AstraZeneca Principal investigator in multiple collaborations with distinguished academic groups from Peking University, Karolinska Institute, Uppsala University, Gothenburg University, University of Virginia, and Harvard University. Johannes joined Ribocure Pharmaceuticals AB from 1st of September 2022 as Head of Bioscience and global projects.

Dr. Anna B Granqvist

Senior Project Director

MSc, PhD

Anna B Granqvist has a PhD in Renal medicine/physiology and experience both from working in Academia (15 years) and big pharma company (10 years at AstraZeneca).
She has a broad experience in pre-clinical models (in vitro and in vivo) and was the renal in vivo Team leader for several year supporting the renal strategy and pipeline build at AstraZeneca. She has been Project leader and principal investigator for both pipeline and technical platform projects as well as collaborations with both academic groups and biotech companies.

Dr. Julia Grönros

Project Director External Innovation

MSc, PhD

Julia Grönros holds a MSc in biology and a PhD in physiology at University of Gothenburg from 2008. She did her post doc at Karolinska Institute in a joint venture with AstraZeneca, Gothenburg. Her research interest is within cardiovascular diseases such as atherosclerosis and myocardial infarction, as well as type 2 diabetes. She has worked extensively with developing preclinical animal models for disease and for target validation, with an expertise in ultrasound imaging techniques. Before joining Ribocure, she worked seven years at the Grants and Innovation Office at University of Gothenburg, as responsible research coordinator in the establishment of a successful research Centre within translational and molecular medicine. Julia joined Ribocure in March 2022 as Project Director for External Innovation.

Pontus Boman

Head of Data Science & IT

MSc

Pontus has more than 30 years of experience from Pharmaceutical and Clinical Development. He has worked within the big pharma, small pharma, CRO, technology vendor and public health care sectors in various positions at AstraZeneca, VGR IT, Oncopeptides, Replior, TFS Health Science and Aixial Group. The focus during the last 20 years has been on biometrics, data science and computerized systems catalyzing clinical trials.
Pontus holds a M.Sc. in Chemical Engineering from Chalmers University of Technology, augmented with various university courses in data science, life science and quality management.

Dr. Felix Gnerlich

Head of Chemistry

Dipl. Chem., PhD

Felix is committed to advancing therapeutic oligonucleotides across various therapeutic areas. He has held key roles at renowned organizations in both the biotech and big pharma sectors.
Equipped with a PhD in organic and nucleic acid chemistry, he joined Sanofi’s Nucleic Acid Therapeutics Platform where he was leading a team specializing in synthesis of therapeutic siRNA and targeted delivery for systemic administration.
Transitioning to Rigontec, a clinical-stage biotech company, he spearheaded the chemistry R&D at the startup leveraging his expertise to implement oligonucleotide chemistry capabilities to develop immunostimulatory RNA as cancer drugs. This company was acquired by the US pharma company Merck, Sharp & Dohme in 2017.
Following this success, Felix ventured into AstraZeneca’s Respiratory & Immunology department aiming to establish oligonucleotide therapeutics for respiratory disease. Throughout his tenure, he played a pivotal role in establishing an early-stage pipeline for oligonucleotide drugs in respiratory diseases and helped enhancing the company’s oligonucleotide drug discovery capabilities.
In February 2024, Felix joined Ribocure as Head of Chemistry.

Malin Westberg

Business Planning Lead

Malin Westberg has over 30 years of experience from administrative roles within the pharmaceutical industry. Between 2016 and 2023, Malin was a Senior Administrator and Team Leader within Pharmaceutical Sciences at AstraZeneca. There, she tackled the challenges of recruitment, planning, and shaping of the newly created department, and working closely with the Head of Business Planning and Operations. Malin particularly excels at strategic partnering and business development.

John Taylor

Chief Business Officer

PhD

John is a Business Development leader and has worked across search & evaluation, due diligence & with transactions. He has an established track record of success concluding many in-licensing & out-licensing deals. He has a strong network across global pharma, biotech, and academic environments.  John spent significant time at AstraZeneca in Business Development in Gothenburg. Before this a biology department head in AZ Lund, Sweden. John also spent ten years at Pfizer as a Project Leader. John has a Ph.D. for studies on DNA-protein recognition with Prof. Steve Halford (FRS) at Bristol. He then studied DNA mismatch repair with Prof. Paul Modrich (Nobel Laureate 2015) at Duke in the USA.

Anders Waas

Business Development Lead

Business Development Lead , Ribocure Pharmaceuticals. 
 
Anders Waas has over three decades of experience in the pharmaceutical, and biotech industry and has significant business development, commercial and R&D experience. He is consultant to GU Ventures in the Life-Science field assisting in establishing start-ups and building companies. He has held senior business development and commercial positions in several pharma companies including AstraZeneca, CVT Therapeutics and Actogenics. He is currently engaged as board member in several start-up and public companies.

Anders Waas

Business Development Lead

Business Development Lead , Ribocure Pharmaceuticals. 
 
Anders Waas has over three decades of experience in the pharmaceutical, and biotech industry and has significant business development, commercial and R&D experience. He is consultant to GU Ventures in the Life-Science field assisting in establishing start-ups and building companies. He has held senior business development and commercial positions in several pharma companies including AstraZeneca, CVT Therapeutics and Actogenics. He is currently engaged as board member in several start-up and public companies.

Ribocure Board

Dr. Li-ming Gan

Chief Executive Officer & Board member

MD, PhD

Chief Executive Officer , Ribocure Pharmaceuticals AB President of Global R&D and Chief Medical Officer, Suzhou Ribo Life Science Co., Ltd.
 
Li-ming Gan is a physician scientist and has 20 years of pharma experience from AstraZeneca. He was responsible for the atherosclerosis and heart failure pipeline between 2007-2011. Between 2011-2013, he worked as a Translational Science Director to help bridging the early projects into the human setting. Between 2013-2018, Li-ming was appointed as a Senior Director Physician, and later Chief Scientist in early clinical research unit and was responsible for phase I and II clinical programs within the cardiovascular area. Until 31st of Dec 2021, Li-ming was VP and Head of Early Clinical Development in early Cardiovascular, Renal and Metabolism Biopharmaceuticals R&D AstraZeneca. Academically Li-ming holds a part-time position as professor and Chief physician at the department of cardiology, Sahlgrenska University Hospital and Sahlgrenska Academy, University of Gothenburg.
 
Since 1st of January 2022, Li-ming joined Suzhou Ribo Life Science Co., Ltd. as President of Global R&D and Chief Medical Officer to devote his career and research focusing on RNA therapeutics. With his joining of Suzhou Ribo Life Science Co., Ltd. Li-ming has also been appointed as CEO for Ribocure Pharmaceuticals AB, a newly established international R&D center of Suzhou Ribo Life Science Co., Ltd. based in Gothenburg, Sweden. This unit will be devoting to developing Suzhou Ribo Life Science Co., Ltd.´s innovative drug projects on the global arena through close collaboration with Scandinavian and European academia and biotechs, global project leadership, as well as innovative clinical development approaches.
dr zicai

Dr. Zicai Liang

Chair of Board

PhD

Chair of Board , Ribocure Pharmaceuticals AB Chief Executive Officer, Suzhou Ribo Life Science Co., Ltd.
 
Dr. Zicai Liang is the founder and CEO of Suzhou Ribo Life Science Co., Ltd. He is responsible for the company’s development and implementation of the R&D strategy for oligonucleotides, as well as the company’s financing and business development plan. Dr. Zicai Liang is a recognized international expert in the field of small nucleic acid technology and therapeutics. He has more than 20 years of experience in research and development of oligonucleotides and is the main initiator of small nucleic acid as therapeutic field in China. He has been a Professor and Head of research at the University of Beijing. He was also Associate Professor at Karolinska Institute in Sweden and Head of department for a research unit. After completing his PhD in molecular mycology at Uppsala University, he was a postdoctoral fellow at Yale University in the United States.
hongyan

Dr. Hongyan Zhang

Board member

PhD

Board member , Ribocure Pharmaceuticals AB President, Suzhou Ribo Life Science Co., Ltd.

Dr Hongyan Zhang is one of the co-founders of Suzhou Ribo Life Science Co., Ltd. Since 2007, she has been the Director of Suzhou Ribo Life Science Co., Ltd. responsible for the overall management and operations of the company. Dr. Hongyan Zhang has more than 20 years of experience in academia and biomedicine. She is an expert in small nucleic acid technology and has vast experience in the establishment and operation of biotechnology companies. Under her leadership, Suzhou Ribo Life Science Co., Ltd. has established a professional and efficient R&D department and from scratch, presided more than ten major new drugs to first time in man. Thereby the company realized the first small nucleic acid therapeutics platform in China. Suzhou Ribo Life Science Co., Ltd. has gathered and trained a large number of high-level professional researchers in small nucleic acid technology and pharmaceuticals, formed the largest innovative research and development platform involving the entire technology chain in Asia. Dr. Hongyan Zhang received her Ph.D. in molecular biology from Uppsala University in Sweden and did her postdoctoral research at Yale University School of Medicine in the United States.

thumbnail_Erik Selin_cropped

Erik Selin

Board member

Business School economist

Erik Selin has over 25 years of experience in investments and corporate leadership across diverse industries. He is the founder and CEO of Fastighets AB Balder and Erik Selin Fastigheter AB. His extensive board commitments include, for example, Norion Bank, Swedish Logistic Property, K-Fast Holding AB, Brinova Fastigheter AB and Hedin Mobility Group AB. Within the medtech industry, Erik also serves as a member of the nomination committee at the Scandinavian orthobiologics company Bonesupport and is chairman of the board at the Swedish medtech company Multi4 Medical.

Science Board

lilach

Professor Lilach Lerman

Advisor renal diseases

MD, PhD

Lilach O. Lerman, MD, PhD, is the Arthur M. and Gladys D. Gray Professor of Medicine and of Physiology in the Mayo Medical School and the Mayo Graduate School. She is the Director of the Renovascular Research Laboratory, Head of the Nephrology Research Unit, and Director of the Regenerative Nephrology Section in the Division of Nephrology & Hypertension at Mayo Clinic. Prof. LO Lerman has been involved in translational nephrology and hypertension research for over 30 years, with a focus on renovascular disease, physiological imaging, the microcirculation, and regenerative medicine.

stephane h

Professor Stephane Heymans

Advisor cardiomyopathies

MD, PhD

Stephane Heymans is Professor of Cardiomyopathies at the Maastricht University Medical Centre and head of Heart Failure Research (2009), Professor of Inflammation and Matrix Biology at the University of Leuven, Cardiovascular Research Department, Belgium (2011). His research focuses on genetic and molecular (inflammatory, fibrotic & metabolic) mechanisms in non-ischemic cardiomyopathies (including HFPEF, myocarditis and dilated cardiomyopathies). Both presently and in the past, he is the chair of different European committees and working groups in the field of myocarditis and cardiomyopathies.
stefano

Professor Stefano Romeo

Advisor NASH and lipids

MD, PhD

Stefano Romeo is Professor in Molecular and Clinical Medicine at the University of Gothenburg and Senior Consultant in Endocrinology at the Sahlgrenska University Hospital. He is also a Faculty Member of the Unit of Human Nutrition at the Department of Medical and Surgical Science, University Magna Graecia, Catanzaro, Italy. Stefano Romeo has an Italian PhD fellowship carried out at the University of Texas Southwestern Medical Center (2006-2009), Dallas, USA, and a Clinical Lectureship at the University of Cambridge, UK (2009-2011). He earned his Medical Degree at Campus Biomedico University in Rome 2001 and completed his residency in Endocrinology and Metabolic Disease 2006 at Sapienza University of Rome. Since 2014, he has been Director of the Lipid Clinic at the Department of Cardiology, Sahlgrenska University Hospital.
JB

Professor Jan Borén

Advisor lipid metabolism

MD, PhD

Jan Borén is Professor in Molecular Medicine and physician at the Department of Clinical Chemistry at the Sahlgrenska University Hospital. His main long-term interest is in lipid metabolism and he has focused on understanding the underlying mechanisms leading to and consequences of lipid accumulation in the liver, arterial wall and heart, with the aim of translating this knowledge into effective treatment. His research programme is translational and involves both in vitro and in vivo studies, including pathophysiological studies and mouse models, as well as kinetic studies in carefully phenotyped human volunteers. He combines research with his position as Director of the Institute of Medicine at the University of Gothenburg.

Zannad

Professor Faiez Zannad

Clinical trialist

MD, PhD

Faiez Zannad is Emeritus
Professor of Therapeutics at Université of Lorraine and Inserm, Nancy, France. He is MD in Cardiology and holds a PhD in Pharmacology. 
As a clinical trialist he has significantly contributed to building most of the trial-based evidence supporting modern heart failure drug therapy. He developed expertise in biomarker and proteomic science. Has served as Chairman of the French Society of Hypertension and of the Working Group on Pharmacology and Drug Therapy of the European Society of Cardiology (ESC). Dr. Zannad is the founder of the Global CardioVascular Clinical Trialists (CVCT) Forum and Workshop, a global think tank dedicated to the science of clinical trials, with meetings in Paris, Washington DC, Asia and the Middle East. Dr. Zannad is recipient of multiple international recognition awards, including as a Highly Cited Researcher award and ESC HFA lifetime achievement award.

caroline

CAROLYN S.P. LAM

Advisor cardiology

MBBS, PhD, FRCP, MS, FACC, FAMS, FESC

Dr Lam is Senior Consultant Cardiologist at the National Heart Center Singapore, and Professor at Duke-National University of Singapore. Dr. Lam is recognized globally for her expertise in heart failure with preserved ejection fraction (HFpEF). She is a world-renowned clinical trialist, having contributed to the first approved treatments for HFpEF through her roles on the global steering committees of the PARAGON, DELIVER, FINEARTS-HF, and EMPEROR-Preserved trials. She served on the 2021–2022 European Society of Cardiology Heart Failure Guidelines Task Force and has published over 750 articles in leading journals, including NEJM, JAMA, Lancet, Circulation, and European Heart Journal, earning recognition as a Clarivate Highly Cited Researcher in Clinical Medicine (2021–2024). Dr. Lam serves as Senior Consulting Editor for JACC and is the recipient of the prestigious 2025 National Outstanding Clinician Scientist Award by the Singapore Ministry of Health. In MedTech, she is co-founder of Us2.ai, an award-winning startup applying artificial intelligence to echocardiography to advance the fight against heart disease.

Contact us for collaboration opportunities and projects ideas!

Ribocure will be expanding heavily in Sweden and looking for new talents to join, and academic associations as well as small and large enterprise partners to collaborate with, with the joint goal of developing highly differentiated and innovative oligonucleotide therapeutics to help patients in need. 

Ribocure Clinic Privacy-policy

Information om behandling av personuppgifter vid Ribocure Clinic

Ribocure Clinic är en avdelning inom Ribocure Pharmaceuticals AB, org.nr 559366-4377, med adress Vetenskapens gränd 11, 431 53 Mölndal (“Ribocure”, ”vi” eller ”oss”).

Ribocure Pharmaceuticals AB är personuppgiftsansvarig för den behandling av personuppgifter som sker inom ramen för Ribocure Clinics verksamhet och som beskrivs i denna integritetspolicy.

[Vid Ribocure Clinic bedriver vi hälso- och sjukvård och omfattas därmed av patientdatalagen (2008:355) (“PDL”). Vi behandlar personuppgifter i enlighet med Europaparlamentets och rådets förordning (EU) 2016/679 (dataskyddsförordningen, “GDPR”), PDL samt övrig tillämplig dataskyddslagstiftning.]

Denna integritetspolicy beskriver vilka personuppgifter vi samlar in via Ribocure Clinic, för vilka ändamål de behandlas, vilken laglig grund som tillämpas, hur länge uppgifterna lagras, hur journalföring sker samt vilka rättigheter du har i förhållande till behandlingen, inklusive rättigheter enligt PDL.

För ytterligare information om Ribocure och Ribocure Clinic hänvisas till www.ribocure.com respektive www.ribocure.com/ribocure-clinic/.

Vid frågor, synpunkter eller klagomål avseende vår behandling av personuppgifter är du välkommen att kontakta vårt dataskyddsombud via e-post: dpo@ribocure.com.

Ändamål och kategorier av personuppgifter

Ribocure Clinic behandlar personuppgifter för ett antal olika ändamål. Nedan beskrivs de huvudsakliga ändamålen, vilka kategorier av personuppgifter som behandlas, vilken laglig grund som tillämpas samt hur länge uppgifterna lagras.

Rekrytering av forskningspersoner och administration av forskningspersonsdatabasen

När du registrerar dig via vårt anmälningsformulär på https://ribocure.com/forskningsperson, eller vid efterföljande kontakter i samband med rekrytering till kliniska studier, sparas dina uppgifter i vår databas över forskningspersoner. Vi behandlar kontaktuppgifter (namn, telefonnummer, e-postadress), hälsoinformation (t.ex. längd, vikt, läkemedelsanvändning och sjukdomshistoria) samt uppgifter om tidigare studiedeltagande. Laglig grund för behandlingen är ditt samtycke (art. 6.1 a GDPR och art. 9.2 a GDPR).

Vi använder uppgifterna för att identifiera lämpliga forskningspersoner, informera dig om aktuella och kommande studier via e-post, sms eller telefon, samt för att administrera kontakten med dig och hantera bokningar av studiebesök. Dina uppgifter

kan finnas kvar i databasen även om du inte deltar i, eller redan har deltagit i, en studie – detta för att möjliggöra kontakt om framtida studier. Uppgifterna lagras så länge samtycke föreligger och raderas eller anonymiseras vid återkallelse av samtycke.

Om du deltar i en klinisk studie kommer ytterligare personuppgifter att behandlas inom ramen för studiens genomförande. Du erhåller separat information om detta, inklusive uppgift om personuppgiftsansvarig, laglig grund och lagringstid, i samband med att du tillfrågas om att delta.

[Hälso- och sjukvård samt journalföring

I den mån Ribocure Clinics verksamhet utgör hälso- och sjukvård är vi skyldiga att föra patientjournal i enlighet med 3 kap. PDL. Vi behandlar härvid uppgifter som är nödvändiga för en god och säker vård, inbegripet identitetsuppgifter (namn, personnummer), kontaktuppgifter, hälsoinformation, uppgifter om diagnoser, undersökningar, behandlingar och vidtagna åtgärder. Laglig grund för behandlingen är rättslig förpliktelse (art. 6.1 c GDPR) och för känsliga personuppgifter behandling som är nödvändig av skäl som hör samman med hälso- och sjukvård (art. 9.2 h GDPR). Patientjournaler bevaras i minst tio (10) år efter sista anteckningen.]

Utbetalning av arvode för studiedeltagande

Vi behandlar kontaktuppgifter (namn), bankuppgifter och personnummer för att kunna betala ut eventuellt arvode för ditt deltagande i studien. Laglig grund för behandlingen är fullgörande av avtal (art. 6.1 b GDPR) samt rättslig förpliktelse (art. 6.1 c GDPR, bokföringslagen). Uppgifterna lagras i sju (7) år i enlighet med bokföringslagen.

Hantering av förfrågningar och övrig kontakt

Vi behandlar kontaktuppgifter (namn, telefonnummer, e-postadress) samt innehåll i kommunikation med dig för att kunna besvara eventuella frågor eller andra kontakter som du har med oss. Laglig grund för behandlingen är berättigat intresse (art. 6.1 f GDPR), närmare bestämt intresset av att administrera och besvara förfrågningar samt informera om vår verksamhet. Uppgifterna lagras så länge det är nödvändigt för att hantera ärendet, dock som längst tolv (12) månader efter senaste kontakt. Kontakta oss om du önskar mer information om hur vi har vägt dina intressen mot våra.

Statistik och analys av webbplatsanvändning (cookies)

Vi behandlar information om din enhet (till exempel webbläsare och IP-adress), uppgifter om användarbeteende och unika besök för att förstå hur du använder vår webbplats och för att förbättra den. Laglig grund för behandlingen är samtycke (art. 6.1 a GDPR). Lagringstiden framgår av vår separata cookiepolicy.

Delning av personuppgifter

Vi kan komma att dela dina personuppgifter med följande kategorier av mottagare: (i) leverantörer av IT-, telefoni- och systemlösningar som tillhandahåller tjänster för administration av forskningspersonsdatabasen och bokning av studiebesök; (ii) sponsorer eller andra aktörer inom ramen för en klinisk studie, i enlighet med vad som framgår av separat studieinformation; samt (iii) myndigheter, i den utsträckning det krävs enligt lag.

Var behandlas dina personuppgifter?

De personuppgifter vi samlar in behandlas huvudsakligen inom EU/EES. I vissa fall kan uppgifter komma att överföras till och behandlas i länder utanför EU/EES (“tredjeland”). Vid sådana överföringar säkerställer vi att lämpliga skyddsåtgärder vidtas i enlighet med kapitel V GDPR, exempelvis genom användning av EU-kommissionens standardavtalsklausuler (art. 46.2 c GDPR) eller genom att mottagarlandet omfattas av ett beslut om adekvat skyddsnivå (art. 45 GDPR). Du kan begära information om vilka skyddsåtgärder som har vidtagits genom att kontakta oss.

[Hur skyddar vi dina personuppgifter?

Ribocure vidtar lämpliga tekniska och organisatoriska åtgärder för att skydda dina personuppgifter mot obehörig åtkomst, förlust, förstöring eller annan otillåten behandling. Åtkomst till patientuppgifter styrs genom behörighetsstyrning och åtkomstkontroll, vilket innebär att endast den personal som behöver uppgifterna i sitt arbete har tillgång till dem. Åtkomst till patientuppgifter loggas systematiskt och loggkontroller genomförs regelbundet. Motsvarande krav ställs på våra leverantörer. Samtliga medarbetare omfattas av sekretessförpliktelser. Ribocure har utsett ett dataskyddsombud som övervakar efterlevnaden av GDPR.]

Dina rättigheter

Du har rätt till:

  • Tillgång (art. 15 GDPR). Du har rätt att få bekräftelse på huruvida vi behandlar personuppgifter om dig och, om så är fallet, få tillgång till uppgifterna samt information om behandlingen. Vi tillhandahåller på begäran en kopia av de personuppgifter som behandlas, utan kostnad.
  • Begränsning av behandling (art. 18 GDPR). Du har under vissa förutsättningar rätt att begära att behandlingen av dina personuppgifter begränsas, exempelvis om du bestrider uppgifternas korrekthet eller har invänt mot behandlingen. En begränsning innebär i praktiken att vi anonymiserar eller markerar uppgifterna och upphör med aktiv behandling under den tid begränsningen gäller.
  • Rättelse (art. 16 GDPR). Du har rätt att begära rättelse av felaktiga personuppgifter samt komplettering av ofullständiga uppgifter eller att få notering om detta i din journal. Om du uppmärksammar att uppgifter om dig är felaktiga eller ofullständiga ber vi dig kontakta oss.
  • Radering (art. 17 GDPR). Du har rätt att begära radering av dina personuppgifter, bland annat om du återkallar ditt samtycke och det inte finns annan laglig grund för behandlingen. Vid radering ur forskningspersonsdatabasen kommer vi att på ett säkert sätt radera eller anonymisera dina uppgifter. Observera att rätten till radering kan vara begränsad om Ribocure har en rättslig skyldighet att bevara uppgifterna, om uppgifterna är nödvändiga för att fastställa, göra gällande eller försvara rättsliga anspråk eller om begäran rör din journal. Vid deltagande i en klinisk studie framgår eventuella begränsningar av den separata studieinformationen.
  • Dataportabilitet (art. 20 GDPR). Du har rätt att få ut de personuppgifter som du har tillhandahållit oss i ett strukturerat, allmänt använt och maskinläsbart format, samt rätt att överföra dessa till en annan personuppgiftsansvarig. Om det är tekniskt möjligt kan du begära direkt överföring. Rätten till dataportabilitet gäller under förutsättning att: uppgifterna har tillhandahållits av dig;
  • behandlingen grundar sig på samtycke eller fullgörande av avtal; och
  • behandlingen sker automatiserat.
  • Invändning (art. 21 GDPR). Du har rätt att invända mot behandling som grundar sig på berättigat intresse. Vid invändning upphör vi med behandlingen om vi inte kan påvisa tvingande berättigade skäl som väger tyngre än dina intressen, rättigheter och friheter.
  • [Spärrning av uppgifter (4 kap. 4 §). När Ribocure Clinic deltar i sammanhållen journalföring har du rätt att begära att dina uppgifter spärras så att andra vårdgivare inte kan ta del av dem. Du har även rätt att begära att uppgifter inom den egna verksamheten spärras för åtkomst av annan personal än den som du har en aktuell vårdrelation med. Observera att en spärrning kan innebära att annan vårdpersonal inte får tillgång till information som kan vara av betydelse för din vård.]
  • [Loggutdrag (8 kap. 5 § PDL). Du har rätt att på begäran ta del av loggar som visar vilken åtkomst som har förekommit till dina patientuppgifter. En begäran om loggutdrag kan göras via de kontaktuppgifter som anges nedan.]
  • Klaga till tillsynsmyndigheten (art. 77 GDPR). Du har rätt att inge klagomål till behörig tillsynsmyndighet om du anser att vår behandling av dina
  • personuppgifter strider mot GDPR. I Sverige är tillsynsmyndigheten Integritetsskyddsmyndigheten (IMY), www.imy.se.

Om du vill utöva någon av ovanstående rättigheter är du välkommen att kontakta oss via de kontaktuppgifter som anges nedan. Vi besvarar din begäran utan onödigt dröjsmål och senast inom en (1) månad. Om du vill inge klagomål till Integritetsskyddsmyndigheten (IMY) kontaktar du dem direkt via www.imy.se.

Kontaktuppgifter

Vid frågor om vår behandling av personuppgifter, begäran om att utöva dina rättigheter eller klagomål, vänligen kontakta oss:

Dataskyddsombud: dpo@ribocure.com 
Allmän e-post: clinic@ribocure.com
Telefon: 0765-278800

Cookies

Cookies är små textfiler som lagras på din enhet när du besöker vår webbplats. Vi använder funktionella cookies som är nödvändiga för webbplatsens tekniska funktion. Därutöver använder vi, med ditt samtycke, cookies för att samla in statistik om användarbeteende och unika besök i syfte att förbättra webbplatsen. Fullständig information om vilka cookies vi använder och hur du hanterar dina cookieinställningar finns i vår separata cookiepolicy på www.ribocure.com/cookie-policy/.

Länkar till externa webbplatser och sociala medier

Våra webbplatser kan innehålla länkar till externa webbplatser och funktioner kopplade till sociala medier. Dessa tredjeparter är självständigt personuppgiftsansvariga för sin behandling av personuppgifter och Ribocure ansvarar inte för sådan behandling. Vi rekommenderar att du tar del av respektive aktörs integritetspolicy innan du lämnar personuppgifter till dem.

Ändringar i informationen

Ribocure förbehåller sig rätten att uppdatera denna integritetspolicy. Den senaste versionen finns alltid tillgänglig på www.ribocure.com/ribocure-clinic/. Vid väsentliga ändringar som påverkar dig informerar vi om detta på webbplatsen och, i förekommande fall, via e-post eller annan elektronisk kommunikation.

Denna integritetspolicy uppdaterades senast den 21 maj 2026.

Ribocure Pharmaceuticals AB Privacy Policy v1.0